Proactive Investors - Run By Investors For Investors

QBioMed appoints Yale psychologist to advisory committee

Dr Pamela Ventola works at Yale University’s Child Study Center where she focuses on behavioral treatments for autism
empty board room
Q BioMed’s drug QBM-001 is being developed for the treatment of autistic children

Q BioMed Inc (OTCQB:QBIO), the New York biotech, announced Wednesday that Dr. Pamela Ventola of Yale University has joined its advisory committee for its QBM-001 clinical program, which is advancing its drug treatment for autistic toddlers.

Dr Ventola now works as a clinical psychologist and assistant professor at Yale University’s Child Study Center where she focuses on behavioral treatments for autism spectrum disorders.

READ: Q BioMed partners with SRI International for autism drug QBM-001

A licensed clinical psychologist, Dr. Ventola is an expert in pediatric neuropsychology and developmental disabilities. She also holds the position of senior science director at the Rare Disease and Pediatric Center of Excellence at Cogstate, a company that supports pharmaceutical companies in clinical trial design.

“Children with [autism spectrum disorders] need safe, effective and targeted treatments that are tested under conditions that take their best interests into consideration to ensure a successful trial,” said Dr. Ventola in a statement. “I am inspired that Q BioMed has the same vision and am excited to ensure QBM-001 has the best chance to help their targeted subgroup.”

Denis Corin, CEO of QBioMed, says Ventola’s expertise will prove helpful as QBioMed prepares its investigational new drug application for QBM-001 to submit to the US Food and Drug Administration.

“[Ventola] is a leader in clinical trial design and biomarker research for the autism spectrum, which is a perfect fit for the subgroup Q BioMed is targeting,” Corin said. “Dr. Ventola will be an asset to our development program as we prepare our Investigational New Drug Application (IND) for submission to the FDA in this important indication for which no drugs are currently available.”

Q BioMed’s drug treatment QBM-001 is being developed and tested for the treatment of minimally verbal and non-verbal toddlers with an autism spectrum disorder.

Contact Ellen Kelleher at [email protected]

View full QBIO profile View Profile

Q BioMed Inc Timeline

Related Articles

September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
January 08 2019
Its plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use